Inge Van de Walle
Company: Argenx
Job title: Research Fellow – Complement Lead
Seminars:
Empasiburbart for MMN: Clinical Update & Biomarker Strategy 4:30 pm
Outlining a comprehensive clinical update on Empasiprubart’s performance in treating MMN, including key efficacy data, patient outcomes, and safety profile from ongoing trials Initiating the full complement pathway, generating inflammatory molecules like C3a, C5a, opsonins, and the membrane attack complex Highlighting GZMK as a previously unrecognized and important contributor to tissue inflammation across various diseases,…Read more
day: Conference Day One